Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0650

0.0%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

Pogeu Mahone

To: Howard Williams who wrote (12279)	8/5/2013 7:01:50 PM
From: NTTG	1 Recommendation of 13111

Howard, please...an award winning Aussie. Re-read your post 12241, why is he now looking at limb perfusion and PV-10? We all thought the story here was IL treatment leads to systemic response that preclude the need for regional or systemic exposure. What has changed since 2009; other than his experience with compassionate care cases and the realization that aggressive stage III and IV patients will not be studied by IL treatment anytime soon? Is there another MM drug in the pipeline that has to exclude those patients too?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next